{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:30:15Z","timestamp":1770748215534,"version":"3.49.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"35","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"NIAID","doi-asserted-by":"publisher","award":["R43AI148018"],"award-info":[{"award-number":["R43AI148018"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.vaccine.2022.07.011","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T23:05:03Z","timestamp":1658444703000},"page":"5103-5113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein"],"prefix":"10.1016","volume":"40","author":[{"given":"Min-Ju","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Ollivault-Shiflett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Schuman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Son","family":"Ngoc Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor A.","family":"Kaltashov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cedric","family":"Bobst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shalini P.","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Przedpelski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph T.","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.vaccine.2022.07.011_b0005","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMra1204186","article-title":"Designing tomorrow's vaccines","volume":"368","author":"Nabel","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.07.011_b0010","unstructured":"Centers for Disease, C. & Prevention Impact of vaccines universally recommended for children--United States, 1990-1998. MMWR Morb Mortal Wkly Rep 48, 243-248 (1999)."},{"key":"10.1016\/j.vaccine.2022.07.011_b0015","unstructured":"Tetanus vaccines: WHO position paper - February 2017. Wkly Epidemiol Rec 92, 53-76 (2017)."},{"key":"10.1016\/j.vaccine.2022.07.011_b0020","first-page":"325","article-title":"Protein Toxins That Utilize Gangliosides as Host Receptors","volume":"156","author":"Dahms","year":"2018","journal-title":"JCI insight"},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.011_b0025","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11910-012-0314-3","article-title":"Tetanus in Ethiopia: unveiling the blight of an entirely vaccine-preventable disease","volume":"12","author":"Woldeamanuel","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.vaccine.2022.07.011_b0030","doi-asserted-by":"crossref","unstructured":"World Health Organization. Electronic address, s.w.i. Tetanus vaccines: WHO position paper, February 2017 - Recommendations. Vaccine 36, 3573-3575 (2018).","DOI":"10.1016\/j.vaccine.2017.02.034"},{"issue":"7736","key":"10.1016\/j.vaccine.2022.07.011_b0035","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/d41586-018-07758-3","article-title":"Vaccine candidates for poor nations are going to waste","volume":"564","author":"Kaslow","year":"2018","journal-title":"Nature"},{"issue":"10063","key":"10.1016\/j.vaccine.2022.07.011_b0040","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1016\/S0140-6736(16)31593-8","article-title":"Global, regional, and national causes of under-5 mortality in 2000\u201315: an updated systematic analysis with implications for the Sustainable Development Goals","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.07.011_b0045","unstructured":"WHO in, Protecting all against tetanus. (ed. K. O'Brien) (World Health Organization (WHO), Avenue Appia 20 1211 Geneva Switzerland; 2019)."},{"issue":"23","key":"10.1016\/j.vaccine.2022.07.011_b0050","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1016\/j.vaccine.2019.04.059","article-title":"Proteomics of diphtheria toxoid vaccines reveals multiple proteins that are immunogenic and may contribute to protection of humans against Corynebacterium diphtheriae","volume":"37","author":"M\u00f6ller","year":"2019","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.011_b0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1017\/S0022172400071084","article-title":"A comparative clinical study of Adsorbed Tetanus Vaccine and Adult-type Tetanus-Diphtheria Vaccine","volume":"89","author":"Deacon","year":"1982","journal-title":"J Hyg (Lond)"},{"key":"10.1016\/j.vaccine.2022.07.011_b0060","doi-asserted-by":"crossref","unstructured":"Pope, C.G. Development of Knowledge of Antitoxins. Br Med Bull 19, 230-234 (1963).","DOI":"10.1093\/oxfordjournals.bmb.a070062"},{"issue":"10","key":"10.1016\/j.vaccine.2022.07.011_b0065","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0264-410X(91)90283-C","article-title":"Adverse reactions after injection of adsorbed diphtheria-pertussis-tetanus (DPT) vaccine are not due only to pertussis organisms or pertussis components in the vaccine","volume":"9","author":"Gupta","year":"1991","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.011_b0070","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/aem.46.3.560-564.1983","article-title":"Isolation and characterization of Corynebacterium diphtheriae nontandem double lysogens hyperproducing CRM197","volume":"46","author":"Rappuoli","year":"1983","journal-title":"Appl Environ Microbiol"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.011_b0075","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.biologicals.2011.05.004","article-title":"Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications","volume":"39","author":"Br\u00f6ker","year":"2011","journal-title":"Biologicals"},{"issue":"10","key":"10.1016\/j.vaccine.2022.07.011_b0080","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.vaccine.2020.01.065","article-title":"Isolation and characterization of new human carrier peptides from two important vaccine immunogens","volume":"38","author":"Wantuch","year":"2020","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2022.07.011_b0085","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1002\/j.1460-2075.1986.tb04527.x","article-title":"Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins","volume":"5","author":"Eisel","year":"1986","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.011_b0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/IAI.01539-13","article-title":"Entry of a recombinant, full-length, atoxic tetanus neurotoxin into Neuro-2a cells","volume":"82","author":"Blum","year":"2014","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.011_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00244-20","article-title":"Tetanus Toxin cis -Loop Contributes to Light-Chain Translocation","volume":"5","author":"Zuverink","year":"2020","journal-title":"mSphere"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.011_b0100","article-title":"A Novel High-Potency Tetanus Vaccine","volume":"11","author":"Przedpelski","year":"2020","journal-title":"Novel High-Potency Tetanus Vaccine mBio"},{"key":"10.1016\/j.vaccine.2022.07.011_b0105","unstructured":"Oganesyan, N., Lees; Andrew, Chang, Min-Ju Vol. 11,060,123. (ed. U.S. Patent) (Fina BioSolutions, LLC (Rockville, MD), USA; 2020)."},{"key":"10.1016\/j.vaccine.2022.07.011_b0110","unstructured":"Oganesyan, N.a.L., Andrew, Vol. 10,093,704. (ed. U.S. Patent) (USA 2015)."},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.011_b0115","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.xphs.2018.03.002","article-title":"Analytical Comparability Assessments of 5 Recombinant CRM197 Proteins From Different Manufacturers and Expression Systems","volume":"107","author":"Hickey","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2022.07.011_b0120","unstructured":"SERVICES, D.O.H.A.H. Bacterial Endotoxins\/Pyrogens. (PUBLIC HEALTH SERVICE, FOOD AND DRUG ADMINISTRATION, 2016)."},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.011_b0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-1033.1991.tb16342.x","article-title":"Limited proteolysis of tetanus toxin. Relation to activity and identification of cleavage sites","volume":"202","author":"Krieglstein","year":"1991","journal-title":"Eur J Biochem"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.011_b0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.biotechadv.2011.05.006","article-title":"Advances and challenges in analytical characterization of biotechnology products: mass spectrometry-based approaches to study properties and behavior of protein therapeutics","volume":"30","author":"Kaltashov","year":"2012","journal-title":"Biotechnol Adv"},{"issue":"2","key":"10.1016\/j.vaccine.2022.07.011_b0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1255\/ejms.480","article-title":"Protein\u2014Ion Charge-State Distributions in Electrospray Ionization Mass Spectrometry: Distinguishing Conformational Contributions from Masking Effects","volume":"8","author":"Gumerov","year":"2002","journal-title":"Eur J Mass Spectrom"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.011_b0140","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/pro.2238","article-title":"Mass spectrometry-based methods to study protein architecture and dynamics","volume":"22","author":"Kaltashov","year":"2013","journal-title":"Protein Sci"},{"issue":"172","key":"10.1016\/j.vaccine.2022.07.011_b0145","doi-asserted-by":"crossref","DOI":"10.3791\/62597","article-title":"Activation and Conjugation of Soluble Polysaccharides using 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP)","author":"Lees","year":"2021","journal-title":"J Vis Exp"},{"key":"10.1016\/j.vaccine.2022.07.011_b0150","unstructured":"Lees, A. Evaluation of Tetanus Toxoids from Various Sources. National Federation of Infectious Diseases Vaccine Conference, Baltimore, MD (April 3-5, 2019)."},{"key":"10.1016\/j.vaccine.2022.07.011_b0155","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2017.04.009","article-title":"The combined use of analytical tools for exploring tetanus toxin and tetanus toxoid structures","volume":"1054","author":"Bayart","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"23","key":"10.1016\/j.vaccine.2022.07.011_b0160","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jchromb.2011.06.003","article-title":"Tetanus toxoid purification: chromatographic procedures as an alternative to ammonium-sulphate precipitation","volume":"879","author":"Stoji\u0107evi\u0107","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.vaccine.2022.07.011_b0165","doi-asserted-by":"crossref","unstructured":"Preneta-Blanc, R., Rigsby, P. Wilhelmsen, Sloth, Tierney, R. Brierley, M. Sesardic, D. Calibration of Replacement International Standard of Tetanus Toxoid for use in Flocculation Test WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION (2007).","DOI":"10.1016\/j.biologicals.2008.05.002"},{"issue":"S2","key":"10.1016\/j.vaccine.2022.07.011_b0170","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/tbed.13455","article-title":"A chemical conjugate of the tick P0 peptide is efficacious against Amblyomma mixtum","volume":"67","author":"Rodr\u00edguez\u2010Mallon","year":"2020","journal-title":"Transbound Emerg Dis"},{"key":"10.1016\/j.vaccine.2022.07.011_b0175","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0952-7915(95)80109-X","article-title":"T cell independent antigens","volume":"7","author":"Mond","year":"1995","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2022.07.011_b0180","unstructured":"Ronald W. Ellis, D.M.G. Development and Clinical Uses of Haemophilus B Conjugate Vaccines, Vol. 11. (Taylor & Francis, 1994)."},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.011_b0185","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.vaccine.2017.12.064","article-title":"Enhancing toxin-based vaccines against botulism","volume":"36","author":"Przedpelski","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.011_b0190","unstructured":"Organization, W.H. in Biologicals Unit & Kansanterveyslaitos (Instirutional Repository for Information Sharing (IRIS) Finland; 1994)."},{"key":"10.1016\/j.vaccine.2022.07.011_b0195","doi-asserted-by":"crossref","unstructured":"Muniandi, K.M., K-R. and Subashkumar, R. Large scale recovery of tetanus toxin and toxoid from fermentation broth by microporous tangential flow filtration. International J of Biotech and Mol Bio Res 4, 28-37 (2013).","DOI":"10.5897\/IJBMBR12.014"},{"key":"10.1016\/j.vaccine.2022.07.011_b0200","unstructured":"Organization, W.H. The immunological basis for Immunization series module 3: Tetanus, Vol. Licence: CC BY-NC-SA 3.0 IGO. (WHO publications, Geneva; 2018)."},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.011_b0205","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1472-765X.2007.02238.x","article-title":"Tetanus toxin production in soy-based medium: nutritional studies and scale-up into small fermentors","volume":"45","author":"Demain","year":"2007","journal-title":"Lett Appl Microbiol"},{"key":"10.1016\/j.vaccine.2022.07.011_b0210","doi-asserted-by":"crossref","first-page":"107781","DOI":"10.1016\/j.biotechadv.2021.107781","article-title":"Meynial-Salles Insights into Clostridium tetani: From genome to bioreactors","volume":"54","author":"Garrigues","year":"2022","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.vaccine.2022.07.011_b0215","first-page":"1173","article-title":"Method of anatoxin vaccination; vaccination against diphtheria and tetanus. Development and results","volume":"82","author":"Ramon","year":"1954","journal-title":"Srp Arh Celok Lek"},{"key":"10.1016\/j.vaccine.2022.07.011_b0220","unstructured":"WHO. (ed. B.U. Rev.1) 1-139 (1977)."},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.011_b0225","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.biologicals.2008.05.002","article-title":"Calibration of replacement international standards of diphtheria and tetanus toxoids for use in flocculation test","volume":"36","author":"Preneta-Blanc","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2022.07.011_b0230","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biologicals.2018.01.003","article-title":"Recommendations of the VAC2VAC workshop on the design of multi-centre validation studies","volume":"52","author":"Halder","year":"2018","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2022.07.011_b0235","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.biologicals.2012.07.011","article-title":"Peter Rigsby, Dorothea Sesardic, Paul Stickings In vitro antigen ELISA for quality control of tetanus vaccines","volume":"40","author":"Laura Coombes","year":"2012","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2022.07.011_b0240","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biologicals.2021.04.002","volume":"71","author":"Riches-Duit","year":"2021","journal-title":"Biologicals"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.011_b0245","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3390\/vaccines8040712","article-title":"Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control Assay","volume":"8","author":"Michiels","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2022.07.011_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biologicals.2017.06.006","article-title":"Drivers and barriers in the consistency approach for vaccine batch release testing: Report of an international workshop","volume":"48","author":"Bruysters","year":"2017","journal-title":"Biologicals"},{"issue":"8","key":"10.1016\/j.vaccine.2022.07.011_b0255","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/00006454-199108000-00002","article-title":"Persistence of serum antibodies elicited by Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infants vaccinated at 3, 5 and 12 months of age","volume":"10","author":"Claesson","year":"1991","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.07.011_b0260","unstructured":"WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 800, 1-221 (1990)."},{"issue":"35","key":"10.1016\/j.vaccine.2022.07.011_b0265","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1016\/j.vaccine.2011.06.039","article-title":"Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate","volume":"29","author":"Yu","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.011_b0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003881","article-title":"A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice","volume":"9","author":"Sayeed","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2022.07.011_b0275","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1128\/iai.45.3.604-609.1984","article-title":"Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule","volume":"45","author":"Volk","year":"1984","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.011_b0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02427384","volume":"8","author":"Matsuda","year":"1992","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.011_b0285","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1128\/IAI.00382-13","article-title":"Enhancing the protective immune response against botulism","volume":"81","author":"Przedpelski","year":"2013","journal-title":"Infect Immun"},{"issue":"46","key":"10.1016\/j.vaccine.2022.07.011_b0290","doi-asserted-by":"crossref","first-page":"7972","DOI":"10.1016\/j.vaccine.2007.06.018","article-title":"Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide","volume":"25","author":"Gudlavalleti","year":"2007","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2022.07.011_b0295","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1080\/21645515.2019.1627816","article-title":"Immunogenicity and safety of a meningococcal serogroups A and C tetanus toxoid conjugate vaccine (MenAC-TT): two immune schedules in toddles aged 12\u201323 months in China","volume":"15","author":"Hu","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"17","key":"10.1016\/j.vaccine.2022.07.011_b0300","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.vaccine.2018.02.085","article-title":"Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study","volume":"36","author":"Klein","year":"2018","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.011_b0305","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/11202760-000000000-00000","article-title":"Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV)","volume":"11","author":"Croxtall","year":"2009","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.vaccine.2022.07.011_b0310","doi-asserted-by":"crossref","unstructured":"Voysey, M. & Pollard, A.J. Seroefficacy of Vi Polysaccharide-Tetanus Toxoid Typhoid Conjugate Vaccine (Typbar TCV). Clin Infect Dis 67, 18-24 (2018).","DOI":"10.1093\/cid\/cix1145"},{"issue":"10","key":"10.1016\/j.vaccine.2022.07.011_b0315","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1172\/JCI119042","article-title":"Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine","volume":"98","author":"Kasper","year":"1996","journal-title":"J Clin Invest"},{"issue":"31","key":"10.1016\/j.vaccine.2022.07.011_b0320","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1016\/j.vaccine.2018.06.037","article-title":"Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis","volume":"36","author":"Jarz\u0105b","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.07.011_b0325","doi-asserted-by":"crossref","first-page":"121143","DOI":"10.1016\/j.ijpharm.2021.121143","article-title":"Predictive modeling for assessing the long-term thermal stability of a new fully-liquid quadrivalent meningococcal tetanus toxoid conjugated vaccine","volume":"609","author":"Neyra","year":"2021","journal-title":"Int J Pharm"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.011_b0330","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/acschembio.1c00272","article-title":"SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies","volume":"16","author":"Valdes-Balbin","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2022.07.011_b0335","doi-asserted-by":"crossref","unstructured":"Micoli, F., Costantino, P. & Adamo, R. Potential targets for next generation antimicrobial glycoconjugate vaccines. FEMS Microbiol Rev 42, 388-423 (2018).","DOI":"10.1093\/femsre\/fuy011"},{"issue":"5","key":"10.1016\/j.vaccine.2022.07.011_b0340","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00520-19","article-title":"Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine Development","volume":"4","author":"Avci","year":"2019","journal-title":"mSphere"},{"issue":"6","key":"10.1016\/j.vaccine.2022.07.011_b0345","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/00006454-199606000-00011","article-title":"Passively acquired anti-tetanus and anti-Haemophilus antibodies and the response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in infancy","volume":"15","author":"Kurikka","year":"1996","journal-title":"Pediatr Infect Dis J"},{"issue":"46","key":"10.1016\/j.vaccine.2022.07.011_b0350","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1016\/j.vaccine.2009.06.013","article-title":"Preparation of bacterial polysaccharide-protein conjugates: analytical and manufacturing challenges","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"issue":"8","key":"10.1016\/j.vaccine.2022.07.011_b0355","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1021\/acs.analchem.7b04748","article-title":"Improving Analytical Characterization of Glycoconjugate Vaccines through Combined High-Resolution MS and NMR: Application to Neisseria meningitidis Serogroup B Oligosaccharide-Peptide Glycoconjugates","volume":"90","author":"Yu","year":"2018","journal-title":"Anal Chem"},{"issue":"7","key":"10.1016\/j.vaccine.2022.07.011_b0360","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/IAI.00477-15","article-title":"A Heterologous Reporter Defines the Role of the Tetanus Toxin Interchain Disulfide in Light-Chain Translocation","volume":"83","author":"Zuverink","year":"2015","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2022.07.011_b0365","unstructured":"(US Patent 11,060,123)."},{"issue":"1","key":"10.1016\/j.vaccine.2022.07.011_b0370","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr Purif"},{"key":"10.1016\/j.vaccine.2022.07.011_b0375","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ttbdis.2015.04.007","article-title":"High efficacy of a 20 amino acid peptide of the acidic ribosomal protein P0 against the cattle tick","volume":"6","author":"Rodriguez-Mallon","year":"2015","journal-title":"Rhipicephalus microplus Ticks Tick Borne Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2022.07.011_b0380","first-page":"777","article-title":"Activation of Soluble Polysaccharides with 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) for Use in Protein-Polysaccharide Conjugate Vaccines and Immunological Reagents","volume":"8","author":"Lees","year":"2020","journal-title":"III Optimization of CDAP Activation Vaccines (Basel)"},{"issue":"11","key":"10.1016\/j.vaccine.2022.07.011_b0385","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/0300-9084(88)90299-4","article-title":"Characterization and biological implications of membrane lectins in tumor, lymphoid and myeloid cells","volume":"70","author":"Monsigny","year":"1988","journal-title":"Biochimie"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22008866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:32Z","timestamp":1759403672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22008866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":77,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0264410X22008866"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetically detoxified tetanus toxin as a vaccine and conjugate carrier protein","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}